Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next-Generation Sequencing-Based Testing for Cancer Patients in International MarketsĀ 

  • Increasing localized access can provide faster results for patients while potentially improving patient outcomes
  • Agreement aims to enable greater access to localized advanced testing capabilities for breast and lung cancer in more than 30 countries where access to affordable advanced genomic testing is lacking or not available

Pfizer and Thermo Fisher Scientific Inc. (NYSE: TMO) today announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associated genes, empowering healthcare providers to select the right therapy for that individual patient. 1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005516/en/

Cancer is a leading cause of death globally, accounting for nearly 10 million deaths in 2020, or around one in six deaths. Breast and lung cancer are the leading types of cancer diagnosed and are responsible for almost 4.5 million deaths worldwide. 2 By 2040, the global burden for cancer is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths. 3 Under the agreement, Thermo Fisher will identify local labs that will be using the company's NGS technology and ensure they have the necessary infrastructure, trained staff, and quality control measures to meet industry standards for NGS testing services for breast and lung cancer. Pfizer will explore ways to enable affordable patient access for NGS testing for these types of cancer and work to raise healthcare provider awareness regarding the benefits of advanced testing. The two companies will continue to evaluate opportunities to expand geographically and to expand testing for other types of cancer.

"Anyone facing a cancer diagnosis should have access to cutting-edge testing that can match them with an appropriate, optimized treatment plan and better inform their care. Today, we aim to bring rapid NGS testing to an increased number of decentralized labs, closer to where patients are treated," said Gianluca Pettiti, executive vice president at Thermo Fisher Scientific. "We are moving one step closer to delivering precision insights to underserved patients so they can receive a more tailored path for their care no matter where they are in the world."

"The more we understand the complex science behind cancer, the better we can treat it. Our experience has taught us that cancer cannot always be treated with a broad brush and often requires an individualized approach based on precise disease characteristics," said Nick Lagunowich, Pfizer Global President of Emerging Markets. "In many parts of the world, access to next-generation sequencing may be limited or unaffordable for cancer patients. This program aims to improve their treatment journey and help increase their chances for improved outcomes."

Single gene testing has historically been used to match patients with appropriate targeted therapies. However, this can be a time intensive process if sequential tests are needed and there may not be enough tissue to run every test ā€“ which may require additional biopsy procedures. As more targeted therapies are available that can be matched through a broader set of genomic markers, next-generation sequencing is quickly replacing sequential, single biomarker tests. By screening a single tumor tissue or blood sample for multiple biomarkers simultaneously, NGS can provide clinical teams with rapid and actionable genomic insights to help inform precision oncology treatment decisions for eligible patients. 4

A retrospective observational real-world data study looked at newly diagnosed stage IV non-small cell lung cancer patients, and found outcomes such as apparent survival and time to next treatment were significantly compromised if actionable mutations were identified after systemic treatment was initiated (e.g. chemotherapy and immunotherapy). However, when treatment was initiated based on molecular results, patients experienced better outcomes compared to patients who were treated prior to receiving molecular results, supporting the need for rapid molecular testing to inform better treatment decisions. 5

About Pfizer Inc.: Breakthroughs that Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com . In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

Disclosure Notice:
The information contained in this release is as of May 9, 2023. Pfizer and Thermo Fisher Scientific assume no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a collaboration agreement between Pfizer and Thermo Fisher Scientific to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether the collaboration between Pfizer and Thermo Fisher Scientific will be successful; uncertainties regarding the impact of COVID-19; and competitive developments.

A further description of risks and uncertainties that affect the businesses of Pfizer and Thermo Fisher Scientific that could cause actual results to differ materially from those indicated by such forward-looking statements can be found in Pfizer's and Thermo Fisher Scientific's respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2022 and in their respective subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results" (in the case of Pfizer) and "Risk Factors" and "Forward-looking Statements" (in the case of Thermo Fisher Scientific) as well as in their respective subsequent reports on Form 8-K. You can access Pfizer's or Thermo Fisher Scientific's filings with the U.S. Securities and Exchange Commission ("SEC") through the SEC website at www.sec.gov or their respective filings through Pfizer's ( www.pfizer.com ) or Thermo Fisher Scientific's ( www.thermofisher.com ) websites, respectively.

__________________________
1 VĆ©ronique Hofman, et al. (2022) JTO 2022: 100457
2 Cancer (who.int)
3 Global Cancer Facts & Figures | American Cancer Society
4 Lemmon, CA et al. (2023) JCO Precision Oncology 2023 :7
5 Smith RE et al. (2022) J Clin Oncol. 40(16_suppl):1530

Media Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com

Pfizer
Media Relations
212-733-1226
PfizerMediaRelations@pfizer.com

Investors Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Investor Relations
(212) 733-4848
IR@pfizer.com

News Provided by Business Wire via QuoteMedia

TMO
The Conversation (0)
CSE:VGW

Valens GroWorks Highlighted by AltaCorp Capital Executive Discussing Flourishing Cannabis Pharma Space

With the launch of a legal recreational cannabis market in Canada, as well as an established medical market, players in the financial and investment spaces have started to look favorably upon cannabis companies leading the industry. In a recent interview on MidasLetter Live,Ā AltaCorp Capital Inc.ā€™s Managing Director David Kideckel spoke about the launch of his companyā€™s cannabis sector coverage, which includes recognizable names in Canada like Auxly Cannabis Group Inc. (TSXV:XLY) andĀ Valens GroWorks Corp.Ā (CSE:VGW).

Speaking of Valens,Ā a Kelowna, BC-based, research-driven, vertically-integrated Canadian cannabis company focusing on cannabis extraction, distillation as well as cannabinoid isolation and purification, Kideckel highlighted the steps the company has taken to deploy its business model.Ā 

Keep reading...Show less
Cannabis Investing

Valens Groworks Announces Strategic Collaboration

Valens GroWorksĀ (CSE:VGW)(CSE:VGW.CN)Ā (the ā€œCompanyā€ or ā€œValensā€œ) and its wholly-owned subsidiary Supra THC Services Inc. (ā€œSupraā€œ) are pleased to announce a collaboration between Supra and Thermo Fisher Scientific (Mississauga) Inc. to develop a ā€œCentre of Excellence in Plant Based Medicine Analyticsā€ centered in Kelowna, British Columbia. This agreement is the first of its kind between a Canadian cannabis company and a world leader in Health Science services, with an ability to deliver innovative technologies, purchasing convenience and comprehensive services to this emerging market.
Supraā€™s operations are located in the Companyā€™s state-of-the-art 17,000 sq ft Kelowna facility, currently undergoing modifications ahead of a significant expansion. Supra will utilize a suite of Thermo Fisher Scientific sector-leading advanced analytical instrumentation to provide analytical services, research and development, forensic analysis and support for clinical trials as well as being a demonstration and training site for Thermo Fisher Scientific clients and third parties involved in this rapidly evolving sector. It will also be used as a regional resource center for universities and companies.
Dr. Rob Oā€™Brien, CEO and Chief Science Officer of Supra THC Services Inc. stated;Ā ā€œThere are many plants such as Cannabis that contain active ingredientsĀ whichĀ could be effective treatments for disease or provide critical health improvements. However, conducting proper clinical trials with materials that contain many active ingredients is challenging,Ā particularlyĀ if the effective absorbed dose can vary significantly depending on how the material is consumed. For example, the effectiveness of absorption of active ingredients contained in an oil carrier is much different if that oil is placed under the patientā€˜s tongue, then if theĀ oil,Ā or edible,Ā is swallowed.Ā ToĀ measure the amount of active ingredients and metabolites in blood, urine, hair and saliva, advanced instrumentation and a team of highly qualified personal is essential. With the Supra THC Services team and advanced instrumentation from Thermo Fisher Scientific, many significant advances are expected.ā€
Luc Dionne, Canadian Sales Manager with Thermo Fisher Scientific (Mississauga) Inc., statesĀ ā€œWe welcome the opportunity to work with Dr. Rob Oā€™Brien and the Supra THC Services team, an organization that conductsĀ testing activities in plant based medicine.Ā Dr. Oā€™Brien has an extensive background in analytical chemistry and is a recognizedĀ authorityĀ in scientific circles. Dr. Oā€™Brien has worked closely with Thermo Fisher ScientificĀ in the pastĀ usingĀ several of our market leading technologies to successfully perform testing on natural products, pharmaceutical formulations and environmental samples. We are delighted that his team has selected Thermo Fisher Scientificā€˜sĀ cost effective analytical testing solutions to promote the advancement of testing protocols to meet the rigorous and regulatory requirements of this market segment.ā€
About Valens GroWorks Corp.
Valens GroWorks Corp. is a CSE-listed company with an aggressive buildout strategy in progress. The Company seeks to capture a broad spectrum of medical cannabis users and adult recreational users once legalized, as well as clinical trial and R&D clients, in pursuit of its ambitious seed-to-sale and farm-to-pharma objectives. The Company also provides management, consulting, testing and support services to domestic and international licensees, as well as financing and managing buildouts of fully-licensed 3rd party operations.
The Company has two wholly-owned subsidiaries based in the Okanagan Valley of British Columbia: 1) Valens Agritech Ltd. (ā€œVALā€) which holds a Health Canada Dealerā€™s License, and 2) Supra THC Services Inc., a Health Canada licensed cannabis testing lab providing sector-leading analytical and proprietary services to Licensed Producers and ACMPR patients. For more information, please visitĀ https:/valensgroworks.com,Ā https://www.valensagritech.comĀ andĀ https://www.suprathc.ca.
AboutĀ Thermo Fisher Scientific (Mississauga) Inc.
Thermo Fisher Scientific (Mississauga) Inc. is a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE: TMO) the world leader in serving science, with revenues of more than US$20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands ā€” Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services ā€” we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visitĀ www.thermofisher.com.
On behalf of the Board of Directors,
VALENS GROWORKSĀ CORP.
(signed)Ā ā€œTyler Robsonā€œ
Chief Executive Officer
For further information, please contact:
Greg Patchell
Telephone: +1.250.860.8634
Notice regarding Forward Looking Statements
This news release contains certain ā€œforward-looking statementsā€ within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as ā€œplanā€, ā€œcontinueā€, ā€œexpectā€, ā€œprojectā€, ā€œintendā€, ā€œbelieveā€, ā€œanticipateā€, ā€œestimateā€, ā€œmayā€, ā€œwillā€, ā€œpotentialā€, ā€œproposedā€ and other similar words, or statements that certain events or conditions ā€œmayā€ or ā€œwillā€ occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
Click here to connect with Valens GroWorks (CSNX:VGW) to receive an Investor Presentation.

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

To help meet increasing demand for cell and gene therapy clinical trialĀ support around the globe, Thermo Fisher Scientific, the world leader inĀ serving science, today announced the expansion of its Fisher BioServicesĀ cryogenic service capabilities in Japan.
This expansion enables itsĀ customers to seamlessly conduct clinical trials across multiple
geographies and provides patients around the world with access to life
changing therapies. As a leading service provider to the cell and gene
therapy community, Fisher BioServices is uniquely positioned with the
experience, resources, and global expertise to support its customers on
their path towards commercialization.
The facility in Tokyo was expanded to include cryogenic storage and
logistics by utilizing a combination of proven components and validated
procedures developed with years of experience in the cell and gene
therapy business. The new modules within this facility allow Fisher
BioServices to configure and replicate each site to meet the specific
requirements of individual clinical trials with minimal variation,
regardless of volume or geographic location. The facility is also
supported by a global comprehensive and integrated Quality System based
on regulatory requirements, industry best practices and trained
personnel.
ā€œJapan is an increasingly important market for cell and gene therapy
companies conducting clinical trials,ā€ said Dennis Barger, Fisher
BioServices vice president and general manager. ā€œThe addition of
cryogenic services to this facility in Japan, combined with our existing
capabilities in Europe and the US, enables us to seamlessly support our
customersā€™ global trials as they develop and commercialize their
therapies.ā€
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc.
(NYSE: TMO) is the world leader in serving science, with revenues of $17
billion and more than 50,000 employees in 50 countries. Our mission is
to enable our customers to make the world healthier, cleaner and safer.
We help our customers accelerate life sciences research, solve complex
analytical challenges, improve patient diagnostics and increase
laboratory productivity. Through our premier brands ā€“ Thermo Scientific,
Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services
ā€“ we offer an unmatched combination of innovative technologies,
purchasing convenience and comprehensive support. For more information,
please visit www.thermofisher.com.

MyDx Provides Positive Mid-Year Update as Part of Special Letter to Shareholders

Highlights:

  • MyDx experiencing double-digit quarterly revenue growth following commercialization of first of four patented technologies
  • Companyā€™s increasing revenues and continued narrowing of losses clears path towards achieving profitability by year-end
  • Enters into first major distribution agreement valued at approximately $4 million for its CannaDx chemical sensor instrument
  • Expects to launch two new sensors by year-end, creating two entire new revenue channels
  • Focusing on substantially decreasing long-term debt and strengthening balance sheet
  • Seeking to aggressively expand sales and marketing initiatives for new products

LA JOLLA, Calif., June 07, 2016 (GLOBE NEWSWIRE) ā€” MyDx, Inc. (OTCQB:MYDX), one of the fastest growing companies in the chemical detection industry and the producer of the patented MyDxā„¢ (My Diagnostic) product line, the first battery operated, handheld, chemical analyzer for consumers, today issued the following Special Letter to Shareholders from its Chairman and Chief Executive Officer Daniel Yazbeck.
ā€œDear Fellow Shareholders,
2016 is off to a strong start, and as we approach the mid-year mark I thought it would be helpful to summarize our progress since launching our multi-use MyDx chemical analyzer with the CannaDx sensor and App.Ā  I will also cover the highlights of our newly accelerated goals for the balance of the year as well as an analysis of the chemical detection marketplace in whose context I believe the MyDx Analyzer can clearly shown to be a market leader.
Before I discuss our goals and strategies looking ahead, I think it is important and prudent for a management team to look back at our accomplishments over the past four years.Ā  Rather than summarizing our many achievements, we thought it would be better communicated via a short video clip we compiled for our investors.Ā  Please click the following link for a quick video summary of the many successes we have had over the past four years that has enabled us to get to where we are today: a much nimbler, stronger and, by far, one of the fastest growing companies in the chemical detection market.
Please click here:Ā MYDX 4 Year Business Plan Accomplishments VideoĀ (https://www.globenewswire.com/NewsRoom/AttachmentNg/ba458e62-5a32-4900-8b8e-29aadd1f6b86)
MyDx Second Half 2016 Key Goals: New Product Launches, Continued Market Penetration and Profitable Growth
Company Prepares for New Products to Enter into Commercialization
On the R&D front, with the recent launch of the next-generation CannaDx SmartPhone App, which expanded our features and updated our database, we are now focusing our effort on the next MyDx Product to enter into commercialization: OrganaDxTM. This application is slated for commercial release by the fourth quarter of this year.
The OrganaDx sensor will help you Trust and Verifyā„¢ the safety of your fruits and vegetables. Specifically, OrganaDx will enable you to measure the pesticide levels in your food, ensuring that you and your family do not unknowingly consume any potentially cancer-causing pesticides. It will empower you to verify, on the spot, whether or not produce is safe for consumption. This is particularly important when buying non-organic produce that are known to be notoriously high in pesticides, commonly referred to as the ā€œDirty Dozen.ā€
The Company expects future sales of OrganaDx should be at a substantially higher margin than our initial product line, which means a strong and growing contribution to our bottom line earnings growth.
Continued Market Penetration
In April 2016, we announced the first of what we expect to be many major retail distribution deals for our leading technology.Ā  Our initial agreement was with Nanolux Technology, Inc. (ā€œNanoluxā€), valued at over $4 million. Nanolux produces one of the worldā€™s leading brands of horticultural lighting ballasts. With over 1,000 retail shops in its distribution network, it has an extensive footprint throughout the U.S. indoor agriculture and hydroponic marketplace concentrated in states with cannabis sales legalized in some form ā€” especially California as the nationā€™s largest legal cannabis market.
We are beginning to actively roll-out our MyDx Analyzers with CannaDx sensors, sales and marketing collateral along with product and sales training to those 1,000 retail shops. Those sales will begin to kick in during the current quarter and are expected to ramp-up steeply throughout the second half of the year, which will provide us with clear visibility of what the remainder of 2016 and even parts of 2017 will look like from a financial and operational perspective.
Increasing Demand for our Initial Product to Enter into Commercialization:Ā  CannaDx
We see the market for CannaDx divided into three segments: consumer direct (primarily our online sales), and growers and dispensaries ā€” both of which we consider prosumers. With online sales strong and growing, and even at high rates globally, that leaves the dispensary market segment still untapped and on which we are aggressively working to sign one or more regional or national distribution deals similar in nature to that of Nanolux.
MyDx is Clearly Positioned for Profitable Growth
Financially, just since its launch in the third quarter of 2015, CannaDx sales have topped well over $500,000, nearly all of which has come through direct-to-consumer sales with minimal marketing effort or expense.
Our net loss has narrowed by approximately $1.6 million year-over-year from ($2.1 million) to ($544,000) in the first quarter ended March 31, 2016. Additionally, we are actively working to reconfigure our manufacturing and supply chain management to scale up for far higher volumes and to reduce unit costs.
Based on these factors, and with the expected new applications in the final stages of development and commercialization, as well as an anticipated jump in CannaDx revenues in the weeks and months ahead driven by retail distribution, we believe we can reach profitability by year end ā€” a significant milestone for MyDx.
Chemical Analyzer Marketplace: MyDxā€™s Growing Leadership Position
Bringing laboratory-based testing and analysis capability out of the lab and placing it in the palm of usersā€™ hands is a common goal throughout the medical device (point of care) and many other industries.
In our industry, it is instructive to consider the hand-held chemical analyzer made by Thermo Fisher ScientificĀ (ā€œTMOā€). TMO bills itself as the ā€œworld leader in serving science,ā€ with revenues of $17 billion and more than 50,000 employees in 50 countries.
TMO developed and launched TruNarcTM, and while not identical in functionality to our CannaDx, it is fairly close, except that TruNarc is priced at close to $20,000 and has cost $400 million in R&D to develop.Ā  Our CannaDx carries a $699 price tag while our multi-use MyDx Chemical Analyzer cost us under $7 million to develop, patent and deploy to market.Ā  TMOā€™s move into the space validates the marketplaceā€™s value, and we applaud however many millions of dollars it spends on sales and marketing since it serves to educate and build the market for both its products as well as our MyDx Analyzer.
MYDX Stock:Ā  Significantly Undervalued
However, we understand we are one of the new entrants into the chemical detection space which is why we trade at such a low valuation compared to heavyweights such as Thermo Fisher.Ā  However, if our past is any indication of what lies ahead for our Company and our shareholders, the Board of Directors and I, personally, strongly believe our stock price will adjust accordingly to our future achievements.Ā  Once we achieve profitability and continue to grow at the pace we expect to, we believe our valuation should be closer to our competitors.Ā  Thermo Fisher, for example, today trades at nearly 30 times 2017 earnings.Ā  Once we provide our 2017 earnings expectations, we think you, as a long-term investor in MyDx, will be very pleasantly rewarded with the patience, confidence and support you have given our Company from the onset.Ā  In fact, we believe the stock is so undervalued here that we are currently contemplating utilizing our excess cash flow to launch our first ever stock buyback program.Ā  We will keep you updated on our Boardā€™s decision on that initiative as soon as it is voted on.
In Summary
I trust this letter enables you to understand the sense of excitement and anticipation we at MyDx have on the outlook for the rest of 2016, and why we eagerly look forward to 2017.
If any of our investors will be in Southern California on Wednesday, June 8, please join us when I present the MyDx investment story and take questions at the 6th Annual LD Micro Invitational Investor Conference at 2:00 pm PDT / 5:00 pm EDT. The conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles and will feature nearly 200 companies in the small-cap universe. The presentation will be broadcast live, as well as archived on our website for 90 days. Hope to see you there.
Sincerely,
/s/ Daniel R. Yazbeck
Chairman and Chief Executive Officer
MyDx, Inc.
AboutĀ MyDx
MyDx, Inc.Ā (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verifyā„¢ what they put into their minds and bodies. The Company has developed MyDx, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of consumersā€™ hands. The multi-use MyDx leverages over a decade of established electronic nose technology to measure chemicals of interest. It owns a substantial and growing intellectual property portfolio of patents covering its technology. With its Canna sensor commercialized, it has four other sensors being developed in its lab that are compatible with the MyDx Analyzer and App.Ā For more information, please visitĀ www.cdxlife.com.
Forward-Looking Statements
This news release contains ā€œforward-looking statementsā€ as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as ā€œmay,ā€ ā€œwill,ā€ ā€œexpect,ā€ ā€œbelieve,ā€ ā€œanticipate,ā€ ā€œestimate,ā€ ā€œintends,ā€ ā€œgoal,ā€ ā€œobjective,ā€ ā€œseek,ā€ ā€œattempt,ā€ or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available atĀ www.sec.gov.

Keep reading...Show less

GE to Buy Thermo Fisher Scientific Businesses for $1.06B

Dividend.com reported that General Electric Companyā€™s (NYSE:GE) healthcare units will purchase life science businesses fromĀ Thermo Fisher Scientific Inc (NYSE:TMO) for $1.06 billion.
As quoted in the market news:

Part of GEā€™s acquisition of TMOā€™s businesses include ā€œculture media and sera, and gene modulation and magnetic beads businesses,ā€ according to theĀ Wall Street Journal. This transaction will expand GE Healthcareā€™s Life Sciences divisionā€™s involvement in cell-related research and medicines.

Keep reading...Show less

Knight Therapeutics Inc. ranks on The Globe and Mail's fifth-annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company") is pleased to announce it will be recognized on The Globe and Mail's 2024 Report on Business magazine's fifth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity.

The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to provide an overview of the largest Canadian corporations with the highest degree of gender diversity among executive ranks. The ranked companies have made tangible and organizational progress related to executive gender parity.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

  • Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: MDT) in December 2023
  • Orchestra BioMed and Terumo remain actively engaged to update operational plans and financial arrangements for Virtue Ā® Sirolimus AngioInfusion TM Balloon ("SAB") development and commercialization for treatment of coronary and peripheral artery disease
  • Expected runway of cash and cash equivalents and marketable securities, including certain potential future proceeds sufficient into 2H 2026, beyond anticipated BACKBEAT top-line results readout

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.

"2023 was a year of strong momentum for Orchestra BioMed as we made significant progress on our cardiovascular pipeline with the achievement of key regulatory milestones and completion of our successful Nasdaq listing," commented David Hochman, chairman, chief executive officer and founder of Orchestra BioMed. "In December, we initiated the BACKBEAT global pivotal study evaluating our lead program, AVIM therapy, in hypertensive pacemaker patients working alongside our strategic partner Medtronic, the global market leader in cardiac pacing therapies. We see a substantial market opportunity for AVIM therapy in this patient population, as well as in other high-risk hypertension populations."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolutā„¢ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access

MedtronicĀ plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolutā„¢ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against AxonicsĀ over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended DecemberĀ 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company") Ā announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Ɨ